Investor

Mito BioPharm has secured seed round funding from Mega Hill Corporation to support the start-up functions of the company. The initial investments fund R&D activities to identify lead compounds for development, CRO-based screening testing and patent filings to secure core intellectual property. Initial administrative and staffing requirements are also supported.

Mito Biopharma is currently seeking A round funding to allow for rapid development of identified lead compounds with targeted IND filing and subsequent phase 1 clinical trials.